- Other markets
- IG services
- Trading platforms
- IG analysis
No data available for this market
BRIEF: For the three months ended 31 March 2015, Enzon Pharmaceuticals Inc revenues decreased 41% to $5.3M. Net income decreased 16% to $7.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects other net primarily gain on sale of asse decrease from $109K (income) to $0K, General and administrative increase of 15% to $583K (expense).
* If your stockbroking account is accessible under the same login as your spread betting or CFD account, you can automatically qualify for our lowest commission rate by placing at least one spread bet or CFD trade in the previous calendar month. See our full charges and fees.